Ovarian Cancer
Conditions
Brief summary
Preliminary evaluation of the efficacy and safety of paclitaxel for injection (albumin-bound) in combination with carboplatin for first-line chemotherapy of ovarian cancer.
Interventions
Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
Sponsors
Huazhong University of Science and Technology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18 to 75 years; * Histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer; * Patients with stage IC-IV according to the International Federation of Obstetrics and Gynecology (FIGO) and who underwent an ideal tumor reduction procedure within 6 weeks prior to enrollment; * Lesion is measurable according to RECIST 1.1 criteria or patient's CA125 is evaluable according to GCIG criteria; * ECOG performance status of 0-2; * Expected survival ≥ 3 months; * Bone marrow function: Neutrophils ≥ 1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥ 90 g/L; * Hepatic and renal function: Serum creatinine ≤ 1.5×ULN; AST and ALT ≤ 1.5×ULN or ≤ 5×ULN in the presence of hepatic metastasis; Total bilirubin ≤ 1.5×ULN, or ≤ 2.5×ULN in patients with Gilbert's syndrome; * Must agree to use effective contraception during the trial; Women of childbearing potential must have a negative serum or urine pregnancy test; Non-lactating patients.
Exclusion criteria
* Ovarian low-grade malignant tumor patients; * Patients who have received abdominal or pelvic radiotherapy; * Patients with central nervous system disease or brain metastases; * Other malignancies have occurred within the last 5 years, except for cervical carcinoma in situ, non-melanoma skin cancers that have been cured; * Prior Grade ≥ 2 sensory or motor neuropathy; * Uncontrolled serious medical conditions that, in the opinion of the investigator, would affect the ability of the subject to receive the study regimen, such as concomitant serious medical conditions, including severe heart disease, cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.; * Known to be hypersensitive, highly sensitive, or intolerant to study-related medications or their excipients; * Receive other study drug chemotherapy within 30 days of the first dose of chemotherapy; * Patients not suitable for participation in this study judged by investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free Survival | 2 year | PFS |
Contacts
Primary ContactDing Ma, M.D.
Backup ContactDanhui Weng, M.D.
Outcome results
None listed